Tech Company M&A Transactions
AurKa Pharma Acquisition
AurKa Pharma, based in Montréal QC, was bought by Eli Lilly & Co. The parties disclosed the acquisition price to be $565 million.
Transaction Overview
Company Name
Acquired By
Announced On
5/16/2018
Transaction Type
M&A
Amount
$565,000,000
M&A Terms
Lilly will acquire all shares of AurKa Pharma. In return, AurKa Pharma shareholders will receive an upfront payment of $110 million. AurKa Pharma shareholders are also eligible to receive up to $465 million in regulatory and sales milestones should AK-01 gain approval in the U.S. and other markets, and achieve certain sales levels.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
Undisclosed
Montréal QC, H1A
Canada
Montréal QC, H1A
Canada
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
AurKa Pharma is a special purpose company created to develop one compound to proof-of-concept. To date, the biopharmaceutical asset has completed GLP toxicology studies.it plans to begin clinical development in Q3-2017.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Caroline Fortier
Browse more venture capital transactions:
Prev: 5/16/2018: Blaze Bioscience venture capital transaction
Next: 5/16/2018: Persosa venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs